CHIEF FINANCIAL OFFICER Ferguson Matthew converted options into 30,287 shares and covered exercise/tax liability with 12,413 shares, increasing direct ownership by 7% to 342,378 units (SEC Form 4)

$ELUT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $ELUT alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ferguson Matthew

(Last) (First) (Middle)
C/O ELUTIA INC.
12510 PROSPERITY DRIVE, SUITE 370

(Street)
SILVER SPRING MD 20904

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ELUTIA INC. [ ELUT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF FINANCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
03/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 03/08/2025 M 1,287(1) A (2) 320,031 D
Class A Common Stock 03/10/2025 F 528(3) D $2.77 325,263(4) D
Class A Common Stock 03/10/2025 M 29,000(1) A (2) 354,263(4) D
Class A Common Stock 03/10/2025 F 11,885(3) D $3 342,378(4) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2) 03/10/2025 M 12,500 (5) (5) Class A Common Stock 12,500 $0 87,500 D
Restricted Stock Units (2) 03/10/2025 M 16,500 (6) (6) Class A Common Stock 16,500 $0 16,500 D
Restricted Stock Units (1) 03/08/2025 M 1,287 (7) (7) Class A Common Stock 1,287 $0 0 D
Explanation of Responses:
1. Transaction represents shares of the Issuer's Class A Common Stock received from the vesting of restricted stock units.
2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
3. Shares withheld by the Issuer to satisfy tax withholding requirements on vesting of restricted stock units.
4. Includes 5,760 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.
5. On January 31, 2024, the Reporting Person was granted 150,000 restricted stock units, Restricted stock units as to 1/6 vest on June 10, 2024, and as to 1/12 vest quarterly on each of the following dates: September 10, 2024, December 10, 2024, March 10, 2025, June 10, 2025, September 10, 2025, December 10, 2025, March 10, 2026, June 10, 2026, September 10, 2026, and December 10, 2026.
6. On January 31, 2024, the Reporting Person was granted 50,000 restricted stock units. Restricted stock units vest as to 34% on September 10, 2024, 33% on March 10, 2025 and 33% on September 10, 2025.
7. On March 8, 2021, the Reporting Person was granted 5,150 restricted stock units, vesting in four substantially equal annual installments beginning on March 8, 2022.
/s/ Jeffrey Hamet, Attorney-in-Fact for Matthew Ferguson 03/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ELUT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ELUT

DatePrice TargetRatingAnalyst
More analyst ratings

$ELUT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29

    SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia's Chief Scientific Officer, will participate in Chardan's Trending Issues in Drug Development Conference Series on Tuesday, April 29, 2025. Chardan's Data & Regulatory Catalysts – Navigating an Evolving Landscape – VirtualFormat: Fireside ChatDate and Time: Tuesday, April 29, 2025, 11:00 a.m. ET (8:00 a.m. PT)Webcast: Click Here A live and archived webcast of the fireside chat will be available in the "Investors" section of the Elutia website at http://investors.elutia.com/. About

    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice

    — Integration of clinical and patient-reported outcomes expected to further differentiate EluPro's utility in cardiac implantable electronic device (CIED) procedures — SILVER SPRING, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the initiation of an EluPro™ clinical study designed to collect patient outcome data in real-world clinical practice. EluPro, the first and only FDA-cleared antibiotic-eluting bioenvelope designed for use with cardiac implantable electronic devices (CIEDs) and neurostimulators, was commercially launched earlier this year. The first patient was enr

    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Elutia Confirms No Material Impact from Global Tariffs

    SILVER SPRING, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today confirmed that the ongoing global tariff environment has had no material impact on its commercial or operational performance. Elutia sources, manufactures, and distributes 100% of its products within the United States, primarily from its Roswell, Georgia production facility and U.S.-based suppliers. These products include EluPro™, CanGaroo®, SimpliDerm®, and its full Cardiovascular portfolio. Furthermore, all Elutia product sales occur within the United States. "We are proud to be a U.S.-based company with all operations and sal

    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ELUT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ELUT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ELUT
SEC Filings

See more

$ELUT
Leadership Updates

Live Leadership Updates

See more
  • Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

    SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries. "We are pleased to welcome Ryan to the Elutia CRU as our new Vice President of Operations," said Dr. Randy Mills, Elutia's Chief Executive Officer. "At Elutia, culture matters, and Ryan has both the experience and character to make him an excellent fit and an effectiv

    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ELUT
Financials

Live finance-specific insights

See more
  • Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

    SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13751810 Please log in approximately 10 minutes prior to the scheduled

    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

    Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024. Business Highlights: First Commercial Use: Announced the first patient implant of EluPro, the FDA-cleared antibiotic-eluting biologic envelope for pacemakers and neurostimulators.Strong Initial Adoption: EluPro is being utilized across all major cardiac implantable electronic device (CIED) brands and in neurostimulation procedures. EluPro now accounts

    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024

    SILVER SPRING, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a leader in drug-eluting biomatrix products, today announced that it will release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information. Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13749386 Please log in approximately 10 minutes prior to the scheduled start time. A l

    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ELUT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more